Despite widespread use of recombinant human EPO, this complication remained undiscovered until a published case series in 2002 linking PRCA with anti-EPO antibodies [13], prompting larger-scale investigations by FDA and European regulators. Here, EPO is linked to pure red-cell aplasia.